Our scientific advisors hail from prestigious international institutions and collectively, have both scientific and clinical expertise in ex vivo cell therapies in immuno-oncology and autoimmunity.
Evren Alici, M.D., Ph.D.
Assistant Professor and Group Leader, Hematology, Karolinska Institutet, Sweden
Chiara Bonini, M.D., Ph.D.
Full Professor, Università Vita-Salute San Raffaele; Deputy Director, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele; and Head, Experimental Hematology Unit, Ospedale San Raffaele, Italy
Daniel DeAngelo, M.D., Ph.D.
Associate Professor of Medicine, Harvard Medical School, and Director, Clinical and Translational Research, Adult Leukemia, Dana Farber Cancer Institute, United States
Saar Gill, M.D., Ph.D.
Assistant Professor of Medicine, Center for Cellular Immunotherapies, University of Pennsylvania, United States
Johanna Olweus, M.D., Ph.D.
Full Professor and Head, Department of Cancer Immunology, University of Oslo, and Director, K.G. Jebsen Center for Cancer Immunotherapy, Norway
E. John Wherry, Ph.D.
Chair, Department of Systems Pharmacology and Translational Therapeutics; Richard and Barbara Schiffrin President's Distinguished Professor of Microbiology; and Director, Institute for Immunology, University of Pennsylvania, United States
Juan Carlos Zúñiga-Pflücker, Ph.D.
Professor and Chair, Department of Immunology, University of Toronto, and Senior Scientist, Sunnybrook Research Institute, Canada
Intellia’s advisors on ex vivo cell therapy in autoimmunity
Laurence Turka, M.D.
Chief Scientific Officer, Rheos Medicines; Deputy Director, Immune Tolerance Network; and Professor of Surgery and Medicine (part-time), Massachusetts General Hospital and Harvard Medical School, United States
Kathryn Wood, D.Phil., F.Med.Sci.
Emeritus Professor of Immunology, Nuffield Department of Surgical Sciences, University of Oxford, United Kingdom